Physician profile
John C Whittington
NPI 1386629632
$1,607.68
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $385 · 2021: $170 · 2022: $133 · 2023: $220 · 2024: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $493.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $184.59 | 2019-2024 | Airsupra |
| Glaxosmithkline, LLC. | $153.36 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $153.26 | 2019-2021 | |
| Amgen INC. | $117.82 | 2019-2023 | Repatha, Otezla |
| Novo Nordisk INC | $114.68 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.30 | 2020-2021 | |
| Pfizer INC. | $98.44 | 2023-2024 | |
| Lilly USA, LLC | $91.03 | 2019-2023 | Emgality, Reyvow |
| Novartis Pharmaceuticals Corporation | $85.91 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $61.17 | 2020-2022 | |
| Amarin Pharma, INC. | $56.80 | 2019-2020 | |
| Abbvie INC. | $50.16 | 2022-2024 | |
| Gilead Sciences, INC. | $44.24 | 2024 | |
| Xeris Pharmaceuticals, INC. | $37.59 | 2022-2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $33.15 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sarepta Therapeutics, INC. | $24.48 | 2022 | |
| Dexcom, INC. | $23.34 | 2023 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $21.62 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.47 | 2023 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2024 | Trintellix |
| Abbott Laboratories | $17.25 | 2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2022 | |
| Impel Pharmaceuticals INC. | $15.02 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $14.30 | 2023 | Gemtesa |
| Lucid Diagnostics INC. | $13.19 | 2023 | |
| Sanofi-Aventis U.S. LLC | $12.82 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $12.17 | 2022 | |
| Medtronic Vascular, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Whittington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.